Share on LinkedInShare on LinkedIn

ARTICLE · 05 APRIL 2016

Novartis Agrees To Settle Bribery Charges Against Chinese Subsidiaries For $25 Million

Ropes & Gray LLP
Ropes & Gray LLP
Contributor
Ropes & Gray LLP

Ropes & Gray LLP

Ropes & Gray is one of the world’s most respected law firms, with offices in key business and...

View firm profile
Explore more from Ropes & Gray LLP

On March 23, 2015, Swiss-based pharmaceutical company Novartis AG reached a civil settlement with the SEC for violating the internal controls and books and records provisions of the FCPA.

GlobalCriminal Law

On March 23, 2015, Swiss-based pharmaceutical company Novartis AG ("Novartis") reached a civil settlement with the United States Securities and Exchange Commission ("SEC") for violating the internal controls and books and records provisions of the Foreign Corrupt Practices Act ("FCPA"), the terms of which included Novartis agreeing to pay $21.5 million in disgorgement of profits, $1.5 million in prejudgment interest, and a $2 million civil penalty. Novartis neither admitted nor denied the SEC's allegations, which claimed that two of Novartis' Chinese subsidiaries engaged in various schemes from 2009 to 2013 to bribe health care professionals ("HCPs") in order to increase sales. According to the SEC administrative order, these Chinese-based business units obscured corrupt payments by instead identifying them as legitimate expenses for conferences, lecture fees, marketing events, education seminars, and medical studies. These false records ultimately were incorporated

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from